15,033 Shares in LivaNova PLC (NASDAQ:LIVN) Purchased by Bayforest Capital Ltd

Key Points

• Bayforest Capital Ltd acquired 15,033 shares of LivaNova PLC, valued at approximately $590,000, according to a recent Form 13F filing.
• Institutional investors now hold 97.64% of LivaNova’s stock, with several hedge funds significantly increasing their stakes in the company during the first and fourth quarters.
• Analysts have mixed ratings on LivaNova, with a consensus buy rating and an average target price of $59.29, reflecting optimism about its future stock performance.

Bayforest Capital Ltd bought a new position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 15,033 shares of the company's stock, valued at approximately $590,000.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Vanguard Group Inc. lifted its stake in LivaNova by 12.7% during the 4th quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock valued at $108,823,000 after acquiring an additional 265,291 shares during the period. Capital Research Global Investors lifted its stake in LivaNova by 19.1% during the 4th quarter. Capital Research Global Investors now owns 1,612,818 shares of the company's stock valued at $74,690,000 after acquiring an additional 258,730 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of LivaNova by 8.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,310,990 shares of the company's stock valued at $60,710,000 after purchasing an additional 107,693 shares during the period. Redmile Group LLC lifted its stake in shares of LivaNova by 19.3% in the 4th quarter. Redmile Group LLC now owns 1,043,539 shares of the company's stock valued at $48,326,000 after purchasing an additional 168,500 shares during the period. Finally, Nuveen Asset Management LLC lifted its stake in shares of LivaNova by 0.6% in the 4th quarter. Nuveen Asset Management LLC now owns 823,412 shares of the company's stock valued at $38,132,000 after purchasing an additional 5,080 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Price Performance

NASDAQ:LIVN traded up $1.36 during trading hours on Monday, reaching $42.49. 466,107 shares of the company were exchanged, compared to its average volume of 693,732. The company has a current ratio of 1.58, a quick ratio of 1.37 and a debt-to-equity ratio of 0.53. The stock's 50-day moving average is $44.64 and its 200-day moving average is $42.83. The firm has a market cap of $2.32 billion, a PE ratio of -10.37 and a beta of 0.92. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $57.35.

Analyst Ratings Changes

Several research firms recently issued reports on LIVN. Robert W. Baird boosted their target price on shares of LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Needham & Company LLC reiterated a "buy" rating and issued a $64.00 target price on shares of LivaNova in a research note on Tuesday, May 13th. Barclays decreased their target price on shares of LivaNova from $56.00 to $55.00 and set an "equal weight" rating for the company in a research note on Thursday, May 8th. Wall Street Zen cut shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, Wolfe Research upgraded shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 target price for the company in a research note on Tuesday, May 20th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $59.29.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.